GridAI Technologies Corp. Common Stock (GRDX) Stock Price
GRDXStock
$4.06+78.92%52W
Market Cap$28.75M
P/E—
PEG Ratio—
Div yield—
Beta1.68
GRDX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)22.95%
Price vs S&P 500 (4W)19.02%
VGM Score52.58
GRDX Analyst Recommendations
Dec 2024
Jan 2025
Feb 2025
Mar 2025
4.00
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GRDXGridAI Technologies Corp. Common Stock | — | — | C | $4.06 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About GridAI Technologies Corp. Common Stock
GridAI Technologies Corp is a late-stage biopharmaceutical company developing non-systemic therapies for gastrointestinal diseases. Key programs include latiglutenase for celiac disease (Phase 3-ready), capeserod for gastroparesis, and adrulipase for pancreatic insufficiency. The company focuses on addressing unmet medical needs in GI health.